11/3/2009

The FDA approved a revised label for diabetes drug Byetta to include reports of problems with kidney function. The decision came days after Eli Lilly and Co. and Amylin Pharmaceuticals received clearance to promote Byetta as a stand-alone treatment for Type 2 diabetes.

Related Summaries